Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

Drug Delivery: Parenteral Route

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

Routes of Drug Administration: Parenteral

Routes of Drug Administration: Parenteral

The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2020

Same author

Antibodies to vaccine antigens in pooled polyclonal human IgG products.

Transfusion·2018

Same author

IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>®</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

Immunotherapy·2018

Same author

Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.

Journal of the peripheral nervous system : JPNS·2018

Same author

Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease.

Respiratory medicine·2017

Same author

Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation.

Blood reviews·2017

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Subcutaneous administration of IgG.

Melvin Berger¹

¹Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA. melvin.berger@uhhospitals.org

Immunology and Allergy Clinics of North America

|October 23, 2008

Summary

Intravenous immunoglobulin (IVIG) transformed treatments for primary immune deficiency diseases (PIDD) and other inflammatory conditions. Subcutaneous immunoglobulin offers a safe, effective, and convenient home-based alternative for patients.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jun 28, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

Immunology
Pharmacology
Clinical Medicine

Background:

Intravenous immunoglobulin (IVIG) became safely available in the 1980s, revolutionizing PIDD treatment.
High-dose IgG demonstrated therapeutic value in autoimmune and inflammatory diseases beyond PIDD.
Advances in IgG therapy have significantly improved patient outcomes and life expectancy.

Purpose of the Study:

To highlight the evolution and impact of immunoglobulin (IgG) therapy.
To discuss the benefits and growing adoption of subcutaneous immunoglobulin (SCIG) administration.
To explore future trends in SCIG for PIDD management.

Main Methods:

Review of historical developments in IgG therapy.
Analysis of clinical outcomes and patient experiences with IVIG and SCIG.
Discussion of technological advancements facilitating SCIG use.

Main Results:

IVIG revolutionized PIDD treatment and expanded IgG's therapeutic applications.
Subcutaneous immunoglobulin (SCIG) provides an effective and safe alternative to IVIG.
Home-based SCIG administration offers greater convenience for many patients.

Conclusions:

IgG therapy, particularly SCIG, has dramatically improved the quality of life for PIDD patients.
SCIG is increasingly utilized, offering a convenient and effective treatment option.
Future advancements in IgG products and delivery systems will further enhance SCIG therapy for PIDD.